QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Xtant Medical Holdings, Inc. (XTNT)

Healthcare

No action
Fundamental
2
Sentiment
2
Technical
1

Do Nothing: fundamentalScore 2 and qualitativeScore 2 are both below the required floor of 3, and avgDollarVolume20 of $86,046.58 is far below the $5,000,000 liquidity floor.

Analysis as of 2026-08-22· more than 2 trading days ago

Company overview

Xtant Medical Holdings, Inc. develops and distributes regenerative medicine products and medical devices, primarily for orthopedic and neurological surgeons. The company's offerings include biomaterials, allograft technologies, and spinal fixation systems, serving both domestic and international markets.

Fundamental

weak
Fundamental2
Speculative turnaround

Xtant Medical's fundamentals are challenged by negative profitability, cash burn, and covenant constraints, indicating a speculative turnaround scenario.

Xtant’s recent SEC filings show a steep post-divestiture revenue reset and a swing back to sizable losses, alongside covenant waivers that tighten financing flexibility. Gross margins remain relatively healthy and EV/Sales looks low, but the combination of cash burn, negative profitability, and distress signals makes this a speculative turnaround rather than a durable fundamental value setup.

Sentiment

weak
Sentiment2
Bearish sentiment

Sentiment is bearish following the Q2 earnings miss and guidance cut, with no positive catalysts identified.

Recent media tone is negative around the 2026-08-11 Q2 update (announced), with last ~14d coverage leaning bearish (polarity_score ≈ -0.22) on miss/guidance-cut framing and operational/supply-chain risk. Baseline sentiment is indeterminate due to a baseline-window extraction error, and legal/court screens surfaced no material cases—leaving post-earnings digestion as the dominant near-term driver.

Technical

very weak
Technical1
Broken structure

Technical indicators show a bearish trend with low liquidity, preventing a viable swing setup.

Bearish/broken structure: XTNT is below SMA20 0.39, SMA50 0.41, SMA200 0.55, EMA9 0.34, EMA21 0.37, and daily VWAP 0.33. MACD remains below zero and below its signal while ADX 34.84 confirms trend strength on the downside; RSI 30.97 is oversold, but not a reversal trigger.

You’re looking at 2026-08-22 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.